Navigation Links
Pooled-Analysis of 54 Clinical Studies Shows No Increased Risk of Heart Attack With Abacavir Therapy
Date:8/6/2008

MEXICO CITY, Aug. 6 /PRNewswire-FirstCall/ -- GlaxoSmithKline (NYSE: GSK) (GSK) announced today that a review of data from over 14,600 patients in 54 clinical studies showed no increased risk of myocardial infarction associated with the anti-HIV medication abacavir. GSK conducted this review upon learning that the analysis undertaken by the D:A:D cohort had found an unexpected but potential association between highly active antiretroviral therapy (HAART) regimens containing abacavir and an increased risk of heart attack. GSK's review of its clinical trial database was presented today at the International AIDS Conference in Mexico City.

The analysis was conducted from a GSK internal database including data from 54 clinical trials. The review pooled data from 9,639 subjects on abacavir-containing HAART and 5,044 subjects on non-abacavir HAART. Overall, less than 30 heart attacks had been reported across the abacavir and non-abacavir groups and no increased risk of heart attack associated with abacavir was observed.

"GSK took the responsibility to examine the existing body of clinical data available to us as soon as we learned the results of the D:A:D cohort," said John Pottage, M.D., Vice President Global Clinical Development at GlaxoSmithKline. "The D:A:D findings were certainly unexpected and are inconsistent with what we have seen with our own data. GSK believes at this time that the D:A:D data are inconclusive."

In the GSK analysis the frequency of coronary artery disorders for both groups was very low and similar to the general population: 2.5 events per 1,000 people in the abacavir HAART and 4 events per 1,000 people in the non-abacavir HAART. Further, the frequency of heart attacks was 1.1 per 1,000 people in the abacavir HAART and 1.4 per 1,000 people in the non-abacavir HAART. GSK's review of clinical and pre-clinical data to date did not reveal a plausible biologic mechanism for the results seen in the D:A:D study.

Inflamma
'/>"/>

SOURCE GlaxoSmithKline
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
4. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
5. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
6. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
7. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
8. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
9. Clinical Trial Effectiveness: How Pharmas & Biotechs Save Cost with Savvy Investigator Management
10. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
11. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/1/2008)...ence Call Scheduled for Tuesday, December 9 at 11:...- , , SOUTH SAN FRANCISCO, Calif., Dec. 1 ...s, Inc. (Nasdaq: SNSS ), a biopharmaceutical com...ion of new oncology therapeutics, today announced ...eloid leukemia (AML) will be presented during the ...
(Date:11/30/2008)... CHICAGO, Dec. 1 Olde...ebral blood flow and a greater number of small blo...sented today at the annual meeting of the Radiolog...The study, conducted at the University of North C...mpare brain scans of older adults who exercise to ...
(Date:11/28/2008)...LIS, Nov. 28 Eli Lilly a...emental New Drug Application (sNDA) from,the U.S....) (duloxetine HCl),for the management of chronic ...the first half of 2009, adding data from a recentl...tis pain of the knee. , The decision does n...
(Date:11/26/2008)... information density, automation and intelligent c...ltrasound to an all new level , , CHICAGO, ... Healthcare ( www.siemens.com/healthcare ) highl... Scanner (ABVS)(1), the world,s first multi-use, ...94th Scientific Assembly and Annual Meeting of the...
Breaking Medicine Technology:Sunesis Announces New Data on Voreloxin for Acute Myeloid Leukemia To Be Presented at ASH 2Sunesis Announces New Data on Voreloxin for Acute Myeloid Leukemia To Be Presented at ASH 3Exercise Helps Prevent Age-Related Brain Changes in Older Adults 2Exercise Helps Prevent Age-Related Brain Changes in Older Adults 3Lilly Withdraws Application for Additional U.S. Indication for Cymbalta(R) for Chronic Pain 2Lilly Withdraws Application for Additional U.S. Indication for Cymbalta(R) for Chronic Pain 3Lilly Withdraws Application for Additional U.S. Indication for Cymbalta(R) for Chronic Pain 4Siemens Introduces New Standard of Care for Breast Ultrasound 2Siemens Introduces New Standard of Care for Breast Ultrasound 3Siemens Introduces New Standard of Care for Breast Ultrasound 4Siemens Introduces New Standard of Care for Breast Ultrasound 5Sexually transmitted disease urinary tract infections may be bad combination for birth defect 22432 1Sexually transmitted disease urinary tract infections may be bad combination for birth defect 22432 2Sexually transmitted disease urinary tract infections may be bad combination for birth defect 22432 3Sickle Cell Drug Underused by Physicians 22429 1Sickle Cell Drug Underused by Physicians 22429 2Global Healer and YouTube Guru Dattatreya Siva Baba Starts Worldwide City Tour on July 2 in New York City 3A Grace Light Is Coming to Solve Mankind 22425 1Global Healer and YouTube Guru Dattatreya Siva Baba Starts Worldwide City Tour on July 2 in New York City 3A Grace Light Is Coming to Solve Mankind 22425 2Warning for teens 3A Teeth and jewelry dont mix 22422 1Warning for teens 3A Teeth and jewelry dont mix 22422 2
...7 - In a late-breaker,presentation at the 42nd Ann...udy of the Liver (EASL), researchers today present...VE 1 clinical trial,which is the first trial to e...ional hepatitis C protease inhibitor telaprevir (T...on (peg-IFN) and,ribavirin (RBV) in treatment-naiv...
... Underway at Nine,Centers, SAN DIEGO, Calif., Apri...armaceutical company, today presented long term,fo...-120, a gene,therapy product in development for th...a 36 percent (p<0.001) reduction in,Parkinson,s sy...red,by the Unified Parkinson,s Disease Rating Scal...
Other Medicine Technology:Interim Results Presented at EASL from PROVE 1 Clinical Trial of,Investigational Drug Telaprevir in Patients with Genotype 1,Hepatitis C 2Interim Results Presented at EASL from PROVE 1 Clinical Trial of,Investigational Drug Telaprevir in Patients with Genotype 1,Hepatitis C 3Interim Results Presented at EASL from PROVE 1 Clinical Trial of,Investigational Drug Telaprevir in Patients with Genotype 1,Hepatitis C 4Interim Results Presented at EASL from PROVE 1 Clinical Trial of,Investigational Drug Telaprevir in Patients with Genotype 1,Hepatitis C 5Interim Results Presented at EASL from PROVE 1 Clinical Trial of,Investigational Drug Telaprevir in Patients with Genotype 1,Hepatitis C 6Interim Results Presented at EASL from PROVE 1 Clinical Trial of,Investigational Drug Telaprevir in Patients with Genotype 1,Hepatitis C 7Interim Results Presented at EASL from PROVE 1 Clinical Trial of,Investigational Drug Telaprevir in Patients with Genotype 1,Hepatitis C 8Ceregene Presents Long Term Follow-Up Data From Phase 1 Trial of,CERE-120 Demonstrating Improved Motor Function in Parkinson's,Patients 2Ceregene Presents Long Term Follow-Up Data From Phase 1 Trial of,CERE-120 Demonstrating Improved Motor Function in Parkinson's,Patients 3Ceregene Presents Long Term Follow-Up Data From Phase 1 Trial of,CERE-120 Demonstrating Improved Motor Function in Parkinson's,Patients 4
(Date:12/1/2008)...ENTO, Calif., Dec. 1 In the face o...to face the nation, the Sutter Health Board of,Di...-billion dollars to fully,fund the Sutter Health ...,often heavily invested in stocks and bonds, have...s worsening economy. Although conservatively,inve...
(Date:12/1/2008)...STER, Minn. - Disturbing evidence of higher mortal...th mitral valve prolapse and severe leakage may be...tion,s severity in women, according to findings of...Annals of Internal Medicine . , Mitral valve pro...ldwide and often requires cardiac surgery, prefera...
(Date:12/1/2008)...-Walker Chooses Two Tampa Beneficiaries for Par an... TAMPA, Fla., Dec. 1 Th...harity of Tampa Bay, Inc. and the Judeo Christian ... the 2009 Par and Poker Celebrity Challenge for Ch... , , "It is only appropriate that events li...
(Date:12/1/2008)...l, nicotine use, personality illnesses common, stu...News) -- Psychiatric disorders are common among yo...tment, a new report shows. , To reach this find... 5,000 respondents, aged 19 to 25, who took part i... Related Conditions. , The study found that 45....
Breaking Medicine News(10 mins):Health News:Sutter Health Invests Hundreds of Millions in Employee Pension 2Health News:Women with mitral valve prolapse are treated less aggressively than men and may be at high risk 2Health News:Celebrity Event Gives Local Non-Profits a Reason to be Thankful 2Health News:Few Young Adults Seek Treatment for Psych Disorders 2
...son died Friday and nearly 500 others who ate at a...he biggest known outbreak of hepatitis A in U.S.//...up by the thousands for vaccinations and no longer... focusing on whether contaminated produce - perhap...
... shows exercise may allow for better brain develop...y engaged.// Researchers from the Oregon Health an...ine if exercise causes physical changes in the bra...for their study because they did not want environm...
...h shows bone marrow stem cells may help restore da...reporting at the American Heart //Association’s Sc...h was a follow-up to a breakthrough trial that too... patient treated with stem cells made from his own...
... shows the symptoms women experience before having...ymptoms they expect to experience. Researchers int...rt attack and were discharged from five different ...men studied was 66. Researchers asked the women to...
Other Medicine News:
...hrotek® Precision Hand Instruments were develo...eel, while still having an instrument with the str...ar of the bending or breaking. Arthrotek Hand Inst... to conform to the surgeon's hand. This new genera...
...hrotek® Precision Hand Instruments were develo...eel, while still having an instrument with the str...ar of the bending or breaking. Arthrotek Hand Inst... to conform to the surgeon's hand. This new genera...
...hrotek® Precision Hand Instruments were develo...eel, while still having an instrument with the str...ar of the bending or breaking. Arthrotek Hand Inst... to conform to the surgeon's hand. This new genera...
...hrotek® Precision Hand Instruments were develo...eel, while still having an instrument with the str...ar of the bending or breaking. Arthrotek Hand Inst... to conform to the surgeon's hand. This new genera...
Medicine Products: